Being an integral and enabling part of the Boston/Cambridge biotech hub is core to the G2D2 strategy. We actively pursue a variety of creative and flexible collaborative models to engage in the world-class science happening here.
e-IND will provide space to Cambridge-based start-up/spin-out companies conducting high-risk but potentially transformative research that can impact the discovery of breakthrough neuroscience therapeutics.
Such companies could be focused on discovering and developing novel therapeutics, or platforms, or both.
The incubator includes dedicated office, biology, chemistry and vivarium capabilities within a state-of-the-art discovery facility.
For informal inquiries and expressions of interest in the incubator contact: G2D2_incubator@eisai.com